<DOC>
	<DOCNO>NCT01452659</DOCNO>
	<brief_summary>The purpose study determine efficacy safety TAK-385 , daily ( QD ) , 12 week woman uterine fibroid .</brief_summary>
	<brief_title>Efficacy Safety TAK-385 Treatment Uterine Fibroids</brief_title>
	<detailed_description>This study Phase II , multicenter , randomize , double-blind , parallel-group , placebo-controlled evaluation efficacy safety TAK-385 10 , 20 , 40 mg ( p.o . ) follow daily administration 12 week woman uterine fibroid .</detailed_description>
	<mesh_term>Leiomyoma</mesh_term>
	<mesh_term>Myofibroma</mesh_term>
	<criteria>1 . The participant diagnose uterine fibroid never receive surgical treatment myoma . 2 . The participant premenopausal woman . 3 . The participant one measurable noncalcified myoma confirm transvaginal sonography . 4 . The participant experience regular menstrual cycle 5 . The participant diagnose menorrhagia 1 . Participants screen Hb &lt; 8 g/dL 2 . Participants previous current history blood disorder 3 . Participants know history severe hypersensitivity severe allergy sanitary good 4 . Participants low abdominal pain due irritable bowel syndrome severe interstitial cystitis 5 . Participants previous current history thyroid dysfunction 6 . Participants previous current history pelvic inflammatory disease 7 . Participants positive PAP smear test result 8 . Participants history panhysterectomy bilateral oophorectomy 9 . Participants judge investigator mark abnormal uterine bleed anovulatory bleed 10 . Participants previous current history malignant tumor 11 . Participants treat follow drug : anticoagulant drug , antiplatelet drug , tranexamic acid , selective estrogen receptor modulator ( SERM ) , activate vitamin D , vitamin D , calcitonin , ipriflavone , steroid hormone , vitamin K , teriparatide , denosumab 12 . Participants treat follow drug : oral contraceptive sex hormone preparation , gonadotropinreleasing hormone ( GnRH ) analogue , dienogest , danazol , aromatase inhibitor 13 . Participants treat bisphosphonate preparation 14 . Participants previous current history severe hypersensitivity severe allergy drug 15 . Participants nondiagnosable abnormal genital bleed 16 . Participants previous current history osteoporosis , bone mass loss , metabolic bone diseases 17 . Participants clinically significant cardiovascular disease uncontrollable hypertension 18 . Participants judge investigator inappropriate participate study base 12lead electrocardiogram ( ECG ) find 19 . Participants active liver disease jaundice , alanine aminotransferase ( ALT ) , aspartate aminotransferase ( AST ) , total bilirubin &gt; 1.5 time upper limit normal ( ULN )</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Drug Therapy</keyword>
</DOC>